Table 1. Summary of patient and tumor characteristics.
| Characteristics | Training Miller LD | Testing Set1 Pawitan Y | Testing Set2 Ivshina AV | Testing Set3 Desmedt D |
| No. of patients | ||||
| 236 | 159 | 249 | 198 | |
| Relapse, No. (%) | ||||
| Relapse | 55 (23%) | 40 (25%) | 89 (35%) | 91 (46%) |
| Non-relapse | 181 (77%) | 119 (75%) | 160 (64%) | 107 (54%) |
| Mean Relapse Free Survival (y) | ||||
| 8.167 | 5.959 | 7.142 | 9.312 | |
| Mean Age (year) | ||||
| 62.51 | 62.12 | 46.39 | ||
| ER status, No. (%) | ||||
| Positive | 201 (85%) | 211 (85%) | 134 (67%) | |
| Negative | 31 (13%) | 34 (13%) | 64 (33%) | |
| NA | 4 (2%) | 4 (2%) | 0 | |
| PG status, No. (%) | ||||
| Positive | 57 (24%) | |||
| Negative | 179 (76%) | |||
| NA | 0 | |||
| Tumor Size(mm) | ||||
| <10 (T 1a, T 1b) | 13 (6%) | 14 (6%) | 9 (4%) | |
| 10–20 (T 1c) | 92 (40%) | 95 (38%) | 59 (30%) | |
| 20–50 (T 2) | 123 (52%) | 129 (52%) | 129 (65%) | |
| >50 (T 3) | 5 (2%) | 10 (4%) | 1 (1%) | |
| Grade, No. (%) | ||||
| 1 | 62 (26%) | 28 (18%) | 68 (27%) | 30 (15%) |
| 2 | 121 (51%) | 58 (36%) | 126 (51%) | 83 (42%) |
| 3 | 51 (22%) | 61 (38%) | 55 (22%) | 83 (42%) |
| NA | 2 (1%) | 12 (8%) | 0 | 2 (1%) |
| Lymph Node Status, No. (%) | ||||
| Positive | 78 (33%) | 81 (32%) | ||
| Negative | 149 (63%) | 159 (64%) | 198 (100%) | |
| NA | 9 (4%) | 9 (4%) | ||
| P53 Mutation Status, No. (%) | ||||
| Mutated | 55 (23%) | 58 (23%) | ||
| Wild Type | 181 (77%) | 189 (76%) | ||
| NA | 0 | 2 (1%) | ||